Table 3.
Individual empiric Bayesian post-hoc parameter estimates for pantoprazole in children, excluding the CYP2C19 poor metabolizer (PM).
| Variable | N | CL/F (L/kg TBW/h) |
CL/F (L/h) |
CL/F (L/h for 70kg TBW) |
Vss/Fb (L/kg TBW) |
Half-life (h) |
|---|---|---|---|---|---|---|
| Age | ||||||
| 6–11 years | 18 | 0.11 (0.06–0.20) | 6.13 (2.64–13.19) | 7.50 (4.04–12.19) | 0.11 | 0.90 (0.65–1.39) |
| 12–17 years | 19 | 0.09 (0.04–0.15) | 9.07 (3.65–16.71) | 7.01 (3.16–11.30) | 0.11 | 1.09 (0.81–1.94) |
| 2C19 genotype | ||||||
| Poor metabolizers | 1 | 0.02 | 1.29 | 1.47 | 0.11 | 3.60 |
| Intermediate metabolizer | 16 | 0.09 (0.04–0.13) | 6.00 (2.64–11.62) | 6.73 (3.16–7.97) | 0.11 | 1.10 (0.82–1.94) |
| Extensive metabolizer | 21 | 0.11 (0.06–0.20) | 8.97 (4.66–16.71) | 7.98 (5.03–12.19) | 0.11 | 0.95 (0.65–1.45) |
Data are presented as median (range). Vss/F was calculated as a sum of Vc/F and Vp/F. All participants had the same TBW normalized Vss/F as no inter-individual variability was estimated on Vc and Vp in the final model.
CL/F, apparent clearance; TBW, total body weight; Vss/F, steady-state volume of distribution.